Table 2.
Univariate and multivariate Cox proportional hazard analysis of overall survival (OS) and time-to-recurrence (TTR)
| Characteristic | Total n | OS
|
TTR
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||
| CIMP/MLH1 methylation | 0.011 | < 0.001 | 0.062 | 0.023 | |||||
| CIMP−/MLH1-U | 70 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | ||||
| CIMP+/MLH1-U | 15 | 2.76 (1.46, 5.19) | 0.002 | 4.73 (2.34, 9.54) | < 0.001 | 2.26 (1.04, 4.88) | 0.039 | 3.33 (1.39, 8.00) | 0.007 |
| CIMP+/MLH1-M | 12 | 0.80 (0.31, 2.07) | 0.649 | 0.43 (0.15, 1.24) | 0.117 | 0.21 (0.03, 1.57) | 0.212 | 0.26 (0.03, 2.10) | 0.204 |
| CIMP−/MLH1-M | 2 | 0 (0, –) | 0.971 | 0 (0, –) | 0.973 | 0 (0, –) | 0.977 | 0 (0, ) | 0.978 |
| Age | |||||||||
| <70 | 64 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | ||||
| ≥70 | 35 | 1.73 (0.99, 3.00) | 0.053 | 2.65 (1.42, 4.92) | 0.002 | 0.27 (0.09, 0.75) | 0.013 | 0.47 (0.15, 1.41) | 0.177 |
| Sex | |||||||||
| Male | 55 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | ||||
| Female | 44 | 0.96 (0.55, 1.67) | 0.887 | 1.45 (0.80, 2.65) | 0.221 | 0.50 (0.24, 1.03) | 0.061 | 0.90 (0.42, 1.94) | 0.790 |
| Stage | |||||||||
| Stage I and II | 29 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | ||||
| Stage III and IV | 70 | 2.72 (1.35, 5.45) | 0.005 | 5.27 (2.25, 12.38) | < 0.001 | 4.88 (1.71, 13.97) | 0.003 | 4.28 (1.26, 14.50) | 0.020 |
| Differentiation | |||||||||
| Well/moderately | 55 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | ||||
| Poorly | 44 | 1.65 (0.95, 2.87) | 0.078 | 1.42 (0.78, 2.56) | 0.252 | 3.01 (1.48, 6.12) | 0.002 | 2.27 (1.06,4.84) | 0.034 |
| Chemotherapy/radiotherapy | |||||||||
| No | 38 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | ||||
| Yes | 61 | 1.42 (0.79, 2.57) | 0.246 | 1.10 (0.55, 2.20) | 0.778 | 3.67 (1.49, 9.03) | 0.005 | 1.87 (0.71, 4.92) | 0.203 |
| KRAS mutations | |||||||||
| Absent | 67 | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | 1.00 (Referent) | ||||
| Present | 32 | 1.09 (0.61, 1.95) | 0.772 | 0.64 (0.34, 1.20) | 0.160 | 1.02 (0.50, 2.09) | 0.960 | 0.51 (0.22, 1.17) | 0.111 |
Abbreviations: OS, overall survival; TTR, time-to-recurrence; HR, hazard ratio; CI, confidence interval; CIMP, CpG island methylator phenotype; MLH1-M, MLH1-methylated; MLH1-U, MLH1-unmethylated; MSS, microsatellite stable; MSI, microsatellite instability